Wikipedia

René Kahn

(Redirected from René S. Kahn)

René Sylvain Kahn (born 1954)[1] is a neuropsychiatrist and the Esther and Joseph Klingenstein Professor and System Chair of Psychiatry at the Icahn School of Medicine at Mount Sinai in the United States, a position he has held since 2017.[2][3][4] He previously served as Professor of Psychiatry and Director of the Brain Center Rudolf Magnus at the University Medical Center Utrecht in the Netherlands. Kahn is recognized for his research on the neurobiology of schizophrenia. He served as a former president of the Schizophrenia International Research Society and was elected to the Royal Netherlands Academy of Arts and Sciences in 2009. He received the Neuropsychopharmacology Award from the European College of Neuropsychopharmacology in 2014.[5][6][7]

René Sylvain Kahn
BornJune 18, 1954
NationalityDutch
CitizenshipNetherlands
EducationUniversity Groningen, University Hospital Utrecht, Academisch Medisch Centrum, Montefiore Hospital, Albert Einstein College of Medicine, Mount Sinai Hospital
Years active1972–1984 (training); 1985–Present (practice)
Medical career
ProfessionNeuropsychiatrist, researcher, professor
InstitutionsIcahn School of Medicine at Mount Sinai
ResearchPsychiatry, schizophrenia

He was awarded a knighthood in the Order of the Netherlands Lion in 2018. As of 2020, he was principal or co-principal investigator of more than 40 grants, written 39 books and book chapters and published more than 1000 peer-reviewed articles.[1]

Biography

edit

Kahn studied medicine from 1972 to 1979 at the University of Groningen, and then specialized in psychiatry and neurology at the University of Utrecht and the Academic Medical Center, respectively. He is a registered neuropsychiatrist since 1986. In 1990 he obtained his Ph.D. with professors Herman van Praag and David de Wied as mentors at the University of Utrecht on the thesis Serotonin Receptor Hypersensitivity in Panic Disorder: an Hypothesis.[8][9]

Kahn served in the Royal Netherlands Army as a first lieutenant in 1980 and 1981.[10]

Following residencies in the Netherlands, he attended the Albert Einstein College of Medicine in New York City for a research fellowship in biological psychiatry. From there he completed psychiatry residencies at Mount Sinai Hospital and then acted as the chief of the psychiatry research unit at the Bronx VA Hospital.[11] In 1993 he returned to the Netherlands be the chair of psychiatry at the University Medical Center. He led the Brain Center Rudolf Magnus[12]—a multi-discipline center for research in fundamental neuroscience, psychiatry, neurology, neurosurgery and rehabilitation medicine—for over 10 years, until 2017.

Honors and awards

edit

Research

edit

Kahn studies biological causes of psychiatric disorders such as schizophrenia and has led numerous consortia examining the brain changes that play a role in schizophrenia.[1] He has coordinated several international trials to optimize the treatment of schizophrenia.

He is known for helping establish proof that schizophrenia debuts with cognitive dysfunction, preceding the onset of the first incidence of psychosis by more than a decade. He and associates further showed that brain volume is one of the most heritable characteristics, paving the way to link brain volumes in health and disease to genetic variation.[1][16][3]

Grants and trials

edit

As of 2020, Kahn is the principal investigator or co-principal investigator on 13 active grants related to child development and drug augmentation for onset schizophrenia to prevent psychosis and cognitive therapy symptoms.[3][17]

Active grant in 2020:

Grants, Contracts and Foundation Sources
Title and No. Role Duration
Stanley Foundation. Prednisolone augmentation for

patients with recent onset schizophrenia[18]

PI 2013-2020
Stanley Foundation. Simvastatin augmentation for recent

onset schizophrenia[19]

PI 2013-2020
EudraCT 2015-003503-39 Stanley Foundation. Omega fatty

aids Trial in Ultra High Risk subjects[20]

PI 2017-2020
NIH/NIMH (1T32MH122394-01) Training the Next

Generation of Clinical Neuroscientists

PI 2020-2024
NIH/NIMH (1U24MH124629-01) Psychosis Risk Evaluation,

Data Integration and Computational Technologies[21]

PI 2020-2024

Publications

edit

Editorial

edit

As of 2020, Kahn is on the editorial board of Schizophrenia Research,[22] European Neuropsychopharmacology, Schizophrenia Bulletin and Early Intervention in Psychosis.[4]

Peer reviewed articles

edit

Kahn authored or co-authored over 1000 scientific papers with an H index, Thomson Reuters: 128; cites: > 73,500 and an H index, Google Scholar: 195; cites: > 165,000.[23]

Partial list:

  • Sher L, Kahn RS. Suicide in Schizophrenia: An Educational Overview. Medicina (Kaunas). 2019 Jul 10;55(7):361. doi: 10.3390/medicina55070361. PMID 31295938; PMCID: PMC6681260.
  • Böttcher C, Schlickeiser S, Sneeboer MAM, Kunkel D, Knop A, Paza E, Fidzinski P, Kraus L, Snijders GJL, Kahn RS, Schulz AR, Mei HE; NBB-Psy, Hol EM, Siegmund B, Glauben R, Spruth EJ, de Witte LD, Priller J. Human microglia regional heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry. Nat Neurosci. 2019 Jan;22(1):78-90. doi: 10.1038/s41593-018-0290-2. Epub 2018 Dec 17. PMID 30559476.
  • Turk E, van den Heuvel MI, Benders MJ, de Heus R, Franx A, Manning JH, Hect JL, Hernandez-Andrade E, Hassan SS, Romero R, Kahn RS, Thomason ME, van den Heuvel MP. Functional Connectome of the Fetal Brain. J Neurosci. 2019 Dec 4;39(49):9716-9724. doi: 10.1523/JNEUROSCI.2891-18.2019. Epub 2019 Nov 4. PMID 31685648; PMCID: PMC6891066.
  • Hess JL, Tylee DS, Mattheisen M; Schizophrenia Working Group of the Psychiatric Genomics Consortium; Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Børglum AD, Als TD, Grove J, Werge T, Mortensen PB, Mors O, Nordentoft M, Hougaard DM, Byberg-Grauholm J, Bækvad-Hansen M, Greenwood TA, Tsuang MT, Curtis D, Steinberg S, Sigurdsson E, Stefánsson H, Stefánsson K, Edenberg HJ, Holmans P, Faraone SV, Glatt SJ. A polygenic resilience score moderates the genetic risk for schizophrenia. Mol Psychiatry. 2019 Sep 6:10.1038/s41380-019-0463-8. doi: 10.1038/s41380-019-0463-8. Epub ahead of print. PMID 31492941; PMCID: PMC7058518.
  • Kahn RS. On the Origins of Schizophrenia. Am J Psychiatry. 2020 Apr 1;177(4):291-297. doi: 10.1176/appi.ajp.2020.20020147. PMID 32233682.
  • Ormel PR, Vieira de Sá R, van Bodegraven EJ, Karst H, Harschnitz O, Sneeboer MAM, Johansen LE, van Dijk RE, Scheefhals N, Berdenis van Berlekom A, Ribes Martínez E, Kling S, MacGillavry HD, van den Berg LH, Kahn RS, Hol EM, de Witte LD, Pasterkamp RJ. Microglia innately develop within cerebral organoids. Nat Commun. 2018 Oct 9;9(1):4167. doi: 10.1038/s41467-018-06684-2. PMID 30301888; PMCID: PMC6177485.
  • Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium. Electronic address: douglas.ruderfer@vanderbilt.edu; Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium. Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell. 2018 Jun 14;173(7):1705-1715.e16. doi: 10.1016/j.cell.2018.05.046. PMID 29906448; PMCID: PMC6432650.
  • Böttcher C, Schlickeiser S, Sneeboer MAM, Kunkel D, Knop A, Paza E, Fidzinski P, Kraus L, Snijders GJL, Kahn RS, Schulz AR, Mei HE; NBB-Psy, Hol EM, Siegmund B, Glauben R, Spruth EJ, de Witte LD, Priller J. Human microglia regional heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry. Nat Neurosci. 2019 Jan;22(1):78-90. doi: 10.1038/s41593-018-0290-2. Epub 2018 Dec 17. PMID 30559476.
  • Böttcher C, Schlickeiser S, Sneeboer MAM, Kunkel D, Knop A, Paza E, Fidzinski P, Kraus L, Snijders GJL, Kahn RS, Schulz AR, Mei HE; NBB-Psy, Hol EM, Siegmund B, Glauben R, Spruth EJ, de Witte LD, Priller J. Human microglia regional heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry. Nat Neurosci. 2019 Jan;22(1):78-90. doi: 10.1038/s41593-018-0290-2. Epub 2018 Dec 17. PMID 30559476.
  • Schür RR, van Leeuwen JMC, Houtepen LC, Joëls M, Kahn RS, Boks MP, Vinkers CH. Glucocorticoid receptor exon 1Fmethylation and the cortisol stress response in health and disease. Psychoneuroendocrinology. 2018 Nov;97:182-189. doi: 10.1016/j.psyneuen.2018.07.018. Epub 2018 Jul 11. PMID 30036796.

Books and chapters

edit

Partial list:

  • Kahn RS. De appel en de Boom. Uitgeverij Balans, Amsterdam 2011. ISBN 9789460032950 (3 editions)
  • Kahn RS. In de spreekkamer van de psychiater. Uitgeverij Balans, Amsterdam 2008. ISBN 9789050188814, NUR 875 (6 printings)
  • Kahn RS. Onze Hersenen., Over de smalle grens tussen normaal en abnormaal. Uitgeverij Balans, Amsterdam 2006, 2007, 2008. ISBN 9050187129, NUR 875 (12 printings)
  • De Haan L, Kahn RS. Psychotische stoornissen. In: Leerboek Psychiatrie (Hengeveld, van Balkom eds). De Tijdstroom uitgeverij, 2005. ISBN 9058980766 / 5898 094 4, NUR 875

References

edit
  1. ^ a b c d "Prof. Dr. René Sylvain Kahn" (PDF). Semmelweis University. Retrieved 2020-02-12.
  2. ^ "René Kahn". Mount Sinai Health System. Retrieved 2020-02-12.
  3. ^ a b c "René Kahn, MD, PhD - MIRECC / CoE". U.S. Department of Veterans Affairs. Retrieved 17 August 2020.   This article incorporates text from this source, which is in the public domain.
  4. ^ a b c d "prof. dr. R.S. (René) Kahn - UMC Utrecht". www.umcutrecht.nl. Retrieved 2020-08-13.
  5. ^ "René S. Kahn, MD, PhD, Appointed Chair of the Department of Psychiatry at Mount Sinai". Mount Sinai Health System. 2016-09-06. Retrieved 2020-02-12.
  6. ^ "Kahn, Prof. dr. R.S. (René)". KNAW. Retrieved 2020-02-12.
  7. ^ a b "Winner 2014: René Kahn, The Netherlands". European College of Neuropsychopharmacology. Retrieved 2020-02-12.
  8. ^ "Neurotree - René S. Kahn". neurotree.org. Retrieved 2020-08-06.
  9. ^ Kahn, Rene S.; Praag, Herman M. Van (1988). "A serotonin hypothesis of panic disorder". Human Psychopharmacology: Clinical and Experimental. 3 (4): 285–288. doi:10.1002/hup.470030409. ISSN 1099-1077. S2CID 145753296.
  10. ^ Weller, Sharon. "On the Origins of Psychiatric Illness: Schizophrenia as an Example". NYPSI. Retrieved 2020-08-06.
  11. ^ Kahn, René S.; Davidson, Michael (1993-03-01). "Serotonin, dopamine and their interactions in schizophrenia". Psychopharmacology. 112 (1): S1–S4. doi:10.1007/BF02245002. ISSN 1432-2072. PMID 7831437. S2CID 2019562.
  12. ^ Sønderby, Ida E.; Gústafsson, Ómar; Doan, Nhat Trung; Hibar, Derrek P.; Martin-Brevet, Sandra; Abdellaoui, Abdel; Ames, David; Amunts, Katrin; Andersson, Michael; Armstrong, Nicola J.; Bernard, Manon (2020). "Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia". Molecular Psychiatry. 25 (3): 584–602. doi:10.1038/s41380-018-0118-1. ISSN 1476-5578. PMC 7042770. PMID 30283035.
  13. ^ "Four professors awarded with the title Doctor Honoris Causa". Semmelweis University. 2014-11-17. Retrieved 2020-08-13.
  14. ^ "Fellows Award advisory committee". MQ: Transforming Mental Health. Retrieved 2020-08-15.
  15. ^ "René Kahn". Royal Netherlands Academy of Arts and Sciences. Archived from the original on 29 November 2020.
  16. ^ Boos, Heleen B. M.; Aleman, André; Cahn, Wiepke; Hulshoff Pol, Hilleke; Kahn, René S. (2007). "Brain volumes in relatives of patients with schizophrenia: a meta-analysis". Archives of General Psychiatry. 64 (3): 297–304. doi:10.1001/archpsyc.64.3.297. ISSN 0003-990X. PMID 17339518.
  17. ^ "Kahn Grants" (PDF). MIRECC. Retrieved October 18, 2020.
  18. ^ Nasib, Lyliana G.; Sommer, Iris E.; Winter - van Rossum, Inge; de Vries, Jacqueline; Gangadin, Shiral S.; Oomen, Priscilla P.; Judge, Gurmeet; Blom, Renske E.; Luykx, Jurjen J.; van Beveren, Nico J. M.; Veen, Natalie D. (2020-06-08). "Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design". Trials. 21 (1): 492. doi:10.1186/s13063-020-04365-4. ISSN 1745-6215. PMC 7278136. PMID 32513294.
  19. ^ Begemann, Marieke J.H.; Schutte, Maya J.L.; Slot, Margot I.E.; Doorduin, Janine; Bakker, P. Roberto; van Haren, Neeltje E.M.; Sommer, Iris E.C. (2015-07-03). "Simvastatin augmentation for recent-onset psychotic disorder: A study protocol". BBA Clinical. 4: 52–58. doi:10.1016/j.bbacli.2015.06.007. ISSN 2214-6474. PMC 4661708. PMID 26674520.
  20. ^ Kahn, Rene (2020-02-10). "Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe". Rene Kahn. {{cite journal}}: Cite journal requires |journal= (help)
  21. ^ "Award Information | HHS TAGGS". taggs.hhs.gov. Retrieved 2020-10-18.
  22. ^ "About the Editors | npj Schizophrenia". www.nature.com. Retrieved 2020-08-16.
  23. ^ "Rene Kahn - Google Scholar". scholar.google.com. Retrieved 2020-08-16.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=René_Kahn&oldid=1188065658"